Fabry Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast
https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Fabry Disease Market Report:
• The Fabry Disease market size was valued approximately USD 1,306 million in 2022 and is anticipated to grow with a significant CAGR of 6.3% during the study period (2023-2032)
• Within the European Union, the United Kingdom and Italy represent the largest market shares, with figures reaching USD 158 million and USD 150 million respectively in 2022. Conversely, Spain holds the lowest market position during the same period, with a recorded figure of USD 44 million.
• In 2022, the Fabry Disease market size reached its peak in the US among the seven major markets (7MM), amounting to approximately USD 625 million. This figure is projected to continue rising through to 2032.
• In 2022, it was estimated that there were 15,290 diagnosed prevalent cases of Fabry Disease across the seven major markets (7MM). Among these, approximately 8,355 cases were reported in the United States alone. It is expected that these numbers will rise during the forecast period.
• In the US, males were more likely than females to have Fabry disease. 4,099 males and 3,809 females were affected by Fabry disease in 2020. According to DelveInsight, the number will rise by 2032
• Key Fabry Disease Companies: Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others
• Key Fabry Disease Therapies: PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others
• The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States
• The Fabry Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

Fabry Disease Overview
The Fabry disease market refers to the pharmaceutical and biotechnology industry's efforts to develop treatments for Fabry disease, a rare genetic disorder caused by mutations in the GLA gene. Fabry disease results in the deficiency of an enzyme called alpha-galactosidase A (α-Gal A), which leads to the accumulation of certain fats, particularly globotriaosylceramide (Gb3 or GL-3), in various cells and tissues throughout the body.

Get a Free sample for the Fabry Disease Market Report:
https://www.delveinsight.com/report-store/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Fabry Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fabry Disease Epidemiology Segmentation:
The Fabry Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Fabry Disease
• Prevalent Cases of Fabry Disease by severity
• Gender-specific Prevalence of Fabry Disease
• Diagnosed Cases of Episodic and Chronic Fabry Disease

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Fabry Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fabry Disease Therapies and Key Companies
• PRX-102: Protalix Biotherapeutics
• AVR-RD-01: AVROBIO
• Venglustat: Sanofi Genzyme
• ST-920: Sangamo Therapeutics
• FLT190: Freeline Therapeutics
• 4D-310: 4D Molecular Therapeutics
• Lucerastat: Idorsia Pharmaceuticals
• Moss-aGal: Greenovation Biotech GMBH
• PRX-102: ICON plc
• pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.
• migalastat: Amicus Therapeutics
• Agalsidase alfa: Shire

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market
https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Fabry Disease Market Strengths
• Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Fabry disease.
• Newborn screening for Fabry disease has been implemented in several countries, enabling the early detection of individuals with Fabry mutations.
• Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy, and substrate reduction therapy.

Fabry Disease Market Unmet Needs
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Fabry Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fabry Disease Companies: Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others
• Key Fabry Disease Therapies: PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others
• Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Fabry Disease Unmet Needs, KOL's views, Analyst's views, Fabry Disease Market Access and Reimbursement

To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Fabry Disease Market Report Introduction
2. Executive Summary for Fabry Disease
3. SWOT analysis of Fabry Disease
4. Fabry Disease Patient Share (%) Overview at a Glance
5. Fabry Disease Market Overview at a Glance
6. Fabry Disease Disease Background and Overview
7. Fabry Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Fabry Disease
9. Fabry Disease Current Treatment and Medical Practices
10. Fabry Disease Unmet Needs
11. Fabry Disease Emerging Therapies
12. Fabry Disease Market Outlook
13. Country-Wise Fabry Disease Market Analysis (2019-2032)
14. Fabry Disease Market Access and Reimbursement of Therapies
15. Fabry Disease Market Drivers
16. Fabry Disease Market Barriers
17. Fabry Disease Appendix
18. Fabry Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Fabry Disease Pipeline https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Fabry Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fabry Disease market. A detailed picture of the Fabry Disease pipeline landscape is provided, which includes the disease overview and Fabry Disease treatment guidelines.

Latest Reports By DelveInsight:

Telemedicine Service Market https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost

Wearable Medical Devices Market https://www.delveinsight.com/report-store/wearable-medical-devices-market
Wearable Medical Devices Market By Device Type (Diagnostic And Monitoring Devices [Vital Sign Monitoring Devices, Sleep Monitoring Devices, Electrocardiographs Fetal And Obstetric Devices, Neuromonitoring Devices, And Others] And Therapeutic Devices [Pain Management Devices, Rehabilitation Devices, Respiratory Therapy Devices, And Others]), By Product Type (Wristband, Headband, Ear Wear, Watch, And Others), By Application (Sports And Fitness, Remote Patient Monitoring, And Home Healthcare), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to a rise in the geriatric population and increasing prevalence of chronic diseases across the globe.

Surgical Robotic System Market https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Robotic Systems Market By Application (Urology, Gynecology, Neurosurgery, Orthopedics, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), And by geography is estimated to register appreciable CAGR forecast till 2028 owing to increase in surgical procedures and rising popularity of minimally invasive surgical interventions.

Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.